Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HALO

Halozyme Therapeutics Inc.

Sep 11 • 04:00PM ET

59.39

Dollar change +0.13
Percentage change 0.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IJH VTI IWM VB VXF VBK XBI IWO MDY IBB

Scroll to Statements

Index	RUT	P/E	23.02	EPS (ttm)	2.58	Insider Own	1.08%	Shs Outstand	126.77M	Perf Week	-4.41%
Market Cap	7.52B	Forward P/E	12.40	EPS next Y	4.79	Insider Trans	-14.12%	Shs Float	125.31M	Perf Month	5.92%
Income	337.29M	PEG	0.82	EPS next Q	1.00	Inst Own	97.27%	Short Float	8.01%	Perf Quarter	18.97%
Sales	873.30M	P/S	8.62	EPS this Y	43.05%	Inst Trans	3.82%	Short Ratio	7.69	Perf Half Y	41.57%
Book/sh	2.29	P/B	25.97	EPS next Y	20.92%	ROA	17.85%	Short Interest	10.04M	Perf Year	58.37%
Cash/sh	4.18	P/C	14.22	EPS next 5Y	28.00%	ROE	153.16%	52W Range	32.83 - 65.53	Perf YTD	60.69%
Dividend Est.	-	P/FCF	18.43	EPS past 5Y	-	ROI	18.82%	52W High	-9.37%	Beta	1.29
Dividend TTM	-	Quick Ratio	6.21	Sales past 5Y	41.16%	Gross Margin	71.52%	52W Low	80.90%	ATR (14)	1.74
Dividend Ex-Date	-	Current Ratio	7.41	EPS Y/Y TTM	50.71%	Oper. Margin	46.04%	RSI (14)	49.64	Volatility	3.02% 2.80%
Employees	373	Debt/Eq	5.30	Sales Y/Y TTM	12.88%	Profit Margin	38.62%	Recom	1.73	Target Price	59.10
Option/Short	Yes / Yes	LT Debt/Eq	5.19	EPS Q/Q	28.90%	Payout	0.00%	Rel Volume	0.55	Prev Close	59.26
Sales Surprise	12.89%	EPS Surprise	23.17%	Sales Q/Q	4.67%	Earnings	Aug 06 AMC	Avg Volume	1.31M	Price	59.39
SMA20	-2.69%	SMA50	4.59%	SMA200	33.39%	Trades		Volume	718,992	Change	0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $27
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform	$17 → $24

Show Previous Ratings

Sep-10-24 06:59AM	Q1 2025 Avid Bioservices Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-05-24 11:31AM	Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-24 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-28-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-27-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
03:03PM	Loading…
Aug-23-24 03:03PM	Halozyme Earnings, Guidance Point to Bullish Future (FX Empire)
Aug-14-24 07:01PM	Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-07-24 04:11PM	How These Two Lesser-Known Biotech Names Obliterated Sales Expectations (Investor's Business Daily)
10:39AM	Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up (Zacks)
Aug-06-24 06:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:50PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:45PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:19PM	Halozyme And Ligand Two Leading Biotechs Smash Quarterly Forecasts (Investor's Business Daily)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
09:16AM	Loading…
Aug-05-24 09:16AM	Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Jul-26-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Jul-23-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:30AM	Halozyme to Report Second Quarter 2024 Financial and Operating Results (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-16-24 05:11PM	Big Money Eyes Halozyme for Strong Growth (FX Empire)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)
Jul-09-24 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Jul-08-24 12:42PM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-03-24 08:00AM	How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin (Investor's Business Daily)
Jul-01-24 10:02AM	3 Breakout Biotech Stocks on Track to Double by 2032 (InvestorPlace)
Jun-25-24 01:15AM	Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Jun-21-24 05:15PM	Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
09:40AM	Loading…
Jun-17-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-13-24 07:00PM	Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Jun-11-24 01:13PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler (Insider Monkey)
09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 01:52PM	Halozyme Therapeutics Scores RS Rating Jump To 91 (Investor's Business Daily)
08:59AM	Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13% (Zacks)
Jun-06-24 11:31AM	Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks) +12.68%
09:31AM	Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU (Zacks)
08:30AM	Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook (PR Newswire)
Jun-05-24 04:05PM	Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform (PR Newswire)
Jun-04-24 04:30PM	Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-31-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-21-24 07:15AM	Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE (PR Newswire)
May-20-24 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
May-16-24 02:55PM	Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating (Investor's Business Daily)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
May-10-24 12:39PM	Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout (Investor's Business Daily)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:10PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:34AM	Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates (Zacks)
08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
07:05AM	Q1 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:52AM	Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-07-24 09:00PM	HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:49PM	Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth (GuruFocus.com)
05:48PM	Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed (MT Newswires)
05:25PM	Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates (Zacks)
04:23PM	Halozyme Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
May-06-24 09:16AM	Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-03-24 04:17AM	How Novo-Catalent Deal Affects Halozyme (HALO)? (Insider Monkey)
Apr-30-24 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-24 04:45PM	Mahesh Krishnan Elected to Halozyme's Board of Directors (PR Newswire)
06:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition (InvestorPlace)
Apr-24-24 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Apr-23-24 08:30AM	Halozyme to Report First Quarter 2024 Financial and Operating Results (PR Newswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-04-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-29-24 06:40AM	The 3 Best Biotech Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-21-24 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? (Zacks)
Mar-19-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Mar-14-24 01:24AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 02:05AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 03:15AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Feb-27-24 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-24 11:26AM	Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag (Zacks) +6.56%
09:00AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 05:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates (Zacks)
04:36PM	Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ... (GuruFocus.com)
04:15PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Feb-14-24 09:15AM	Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
06:49AM	Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook (Insider Monkey)
Feb-13-24 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-08-24 04:30PM	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results (PR Newswire)
Jan-29-24 04:15PM	Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jan-26-24 09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-24-24 12:10PM	Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-22-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HELEN TORLEY	Officer	Sep 11 '24	Proposed Sale	59.09	10,000	590,873		Sep 11 04:05 PM
HELEN TORLEY	Officer	Sep 10 '24	Proposed Sale	59.09	10,000	590,897		Sep 10 04:16 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Jan 03 '24	Option Exercise	0.00	7,611	0	12,418	Jan 05 04:04 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Option Exercise	13.55	10,000	135,547	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Option Exercise	12.07	10,000	120,700	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Sale	40.39	10,000	403,940	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Sale	39.63	10,000	396,322	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Option Exercise	14.32	10,000	143,173	160,203	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Option Exercise	13.81	10,000	138,100	161,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Sale	39.79	10,000	397,880	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Sale	39.08	10,000	390,790	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Option Exercise	19.98	10,000	199,800	161,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Sale	36.52	10,000	365,200	151,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Option Exercise	19.98	10,000	199,800	161,911	Sep 19 04:09 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Sale	39.10	10,000	390,980	151,911	Sep 19 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc.

Upgrade your FINVIZ experience